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1. Introduction 
Succinic semialdehyde (SSA) is an intermediate of
the 4-aminobutyrate shunt pathway (GABA-shunt). 
In mammals, this pathway is particularly important 
in the brain [l]; this was bypass calculated to account 
for 10% of the flux through the Krebs cycle [2]. In 
brain, SSA is primarly oxidized to succinate by a spe- 
cific dehydrogenase which has been purified and char- 
acterized from several species (reviewed [3]). How- 
ever, brain tissue can also reduce SSA to vhydroxy 
butyrate (GHB) [4] and recently the enzyme(s) re- 
sponsible have been identified as NADPH-dependent 
aldehyde reductases [5]. The biosynthesis of GHB in 
brain tissue is of great interest as this compound which 
occurs naturally in the brain [6] induces anaesthesia 
when administered toman and animals in relatively 
large doses [7]. Although the degree to which this 
reductive pathway operates in vivo is not as yet 
known, the recent isolation from human brain of a 
fairly specific SSA reductase 181 and these similar 
results using rat brain as the enzyme source, strongly 
support he hypothesis that GHB biosynthesis may be 
a significant pathway of pharmacological interest. 
2. Materials and methods 
Biogenic aromatic aldehydes were obtained by 
incubation of the parent amines with rat liver mono- 
amine oxidase 191. 
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For qualitative assays of column eluates, 50 ti 
enzyme samples were pipetted into tubes of cold 
100 mM potassium phosphate buffer (pH 7), con- 
taining 5 mM 2-mercaptoethanol and 2 X lOA M 
SSA or p-nitrobenzaldehyde. The reaction was 
started by rapid addition of NADPH to 5 X lo-” M 
final cont. in a 1 ml total vol. and subsequent incuba- 
tion for 30 min at 3?C!. Then the decrease in NADPH 
fluorescence in the samples was measured at excita- 
tion 355 mn and emission 470 nm. 
Qu~titative enzyme assays were performed by 
direct recording of the initial rate of NADPH oxida- 
tion at 37°C in a double beam spectrophotometer at 
340 nm, assuming an absorbance of 6.22 X lo3 for 
NADPH. The volume and composition of the incuba- 
tion medium were identical to that described for the 
qualitative assay, except hat the, pH was 6.0 and the 
reference cuvette contained no aldehyde substrate. 
The reaction was started by addition of enzyme. 
2.2. Enzyme extraction and p~.~~tion 
Adult Wistar ats (50) were stunned, decapitated 
and the brains rapidly removed and suspended in
400 ml final vol. of cold 2 mM potassium phosphate 
buffer (pH 7) containing 1 X lo4 M glutathione and 
1 X lo4 M phenyhnethylsulphonyl fluoride. 
All subsequent operations were done at 4°C. The 
suspension was homogenized at maximum speed for 
3 min in a food blender. The homogenate was then 
centrifuged for 1 h at 30 000 X g and concentrated 
KC1 solution was added to the resultant clear super- 
natant solution to 100 mM fmal cont. 
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2.3. Column chromatography The pooled active fractions were stored at +4’C. 
All rinsing and elution buffers contained 5 mM 
2.mercaptoethanol and 5 mM potassium phosphate 
(pH 7.2) up to the two final chromatographic steps 
where the pH was 7.8. The supernatant was absorbed 
onto a 1.6 X 13 cm column of blue Sepharose (Phar- 
macia). The column was rinsed with phosphate buffer 
(pH 7.2) containing 100 mM KCl, and then with the 
same buffer minus the KCl. The outlet of the blue 
Sepharose column was then attached to a 1.6 X 14 cm 
column of DEAE-cellulose (Whatman DE 52). The 
blue Sepharose column was then eluted directly onto 
the DEAE-cellulose column with 100 ml of 1 X 
lOA M Cibacron blue (Ciba-Geigy) dissolved in the 
above rinsing buffer. The dye is firmly retained as a 
narrow band at the top of the DEAE-cellulose column. 
The DEAE-cellulose column was separated from the 
blue Sepharose column and rinsed with buffer before 
elution with 400 ml linear gradient of O-200 mM 
KC1 in the same buffer. Fractions of 6 ml were col- 
lected. It is at this stage that two succinic semialde- 
hyde reductases are separated and thus they will now 
be referred to as SSR 1 and SSR 2 which is the order 
in which they are eluted from the DEAE-cellulose 
column. Both enzymes were then treated separately 
but almost identically. The enzymes were concen- 
trated to -10 ml in an Amicon cell equipped with a 
PM 10 membrane, then diluted to -100 ml and recon- 
centrated and rediluted in order to lower the KC1 
concentration. They were then adsorbed onto 1.6 X 
7 cm columns of QAE Sephadex (Pharmacia) columns. 
After rinsing with starting buffer, enzyme SSR 1 was 
eluted with a linear gradient of 200 ml 0- 100 mM 
KCl, and enzyme SSR 2 with the same volume of 
50-250 mM KCl. Fractions of 4 ml were collected. 
The final two chromatographic steps were carried out 
at pH 7.8 and were identical for each enzyme. The 
active fractions from the QAE Sephadex columns 
were concentrated to 5 ml and applied to a 2.6 X 
100 cm column of Sephadex G-150 (Pharmacia). 
Elution was carried out with potassium phosphate 
buffer 5 mM (pH 7.8) containing 5mM 2.mercapto- 
ethanol and 6 ml fractions were collected. The active 
fractions were adsorbed irectly onto a 0.9 X 16 cm 
column of 2’,5’-ADP Sepharose (Pharmacia). After 
rinsing with potassium phosphate buffer 5 mM 
(pH 7.8) containing 1 X lo4 M glutathione con- 
taining in addition 1 X 10e4 M glutathione, the 
enzymes were eluted with a linear gradient of 100 ml 
O-l X lo-’ M NADP and collected in 3 ml fractions. 
2.4. Protein determinations 
The Folin method [lo] was used up to the DEAE- 
Sepharose step and thence the densitometry of the 
stained protein bands on SDS gels. Bovine serum 
albumin was used as the standard. 
2.5. Molecular weight determinations 
These were determined using appropriate molec- 
ular weight markers by SDS-polyacrylamide gels 
[ 1 l] and non-denaturing gels of different polyacryl- 
amide concentrations [ 121. 
2.6. pH optima 
These were measured for the two enzymes for 
both the forward and reverse reactions. For the for- 
ward reaction the standard reaction mixture was 
employed in 100 mM potassium phosphate buffers. 
For the reverse reaction, 100 mM phosphate buffer 
was used up to pH 8.0 and thereafter 100 mM borate 
buffers. The substrate concentrations were GHB = 
10 mM and NADP = 5 X lo4 M. 
2.7. K,,, values 
For the forward reaction the Km values for SSA 
were measured in the standard reaction medium 
(pH 6) containing 5 X lo-’ M NADP. The Km values 
for NADPH were obtained similarly at a SSA concen- 
tration of 2 X lo4 M. Km values for GHB in the 
reverse reaction were measured in 100 mM phosphate 
buffer (pH 8.1) at 5 X lo4 M NADP and the values 
for NADP were similarly determined at 1 X lo-* M 
GHB. 
2.8. Substrate specificities and inhibition 
For both enzymes, various aldehydes at 2 X 1 O4 M 
were substituted for SSA in the standard reaction 
medium at pH 6 and the relative initial reaction veloc- 
ities compared. Potential inhibitors were similarly 
tested using 2 X lo4 M SSA as substrate. 
3. Results 
Fig.1 shows the separation of 3 peaks of aldehyde 
reductase activity by DEAE-cellulose chromato- 
graphy; the first peak (SSR 1) is active with both SSA 
and p-nitrobenzaldehyde. The second peak reduced 
only p-nitrobenzaldehyde whereas the third peak 
(SSR 2) was specific for SSA. 
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Activity, 
srbitrary units 
fraction XV 
Fig.]. DEAE-cellulose chromatography: (0) Activity with succinic semialdehyde; (r) Activity with 4nitrobenzaldehyde; (o) Azs4 
Table 1 
Purification of two SSA reductases from 50 rat brains 
Fraction Volume Units Total Protein units/ Yield Purification 
(ml) /ml units (mglml) mg protein (%I (-fold) 
SSR 2 
Supernatant 
+ Blue Sepharose 
DEAE-cellulose 
QAE-Sephadex 
Sephadex G-150 
ADP-Sepharose 
SSR 1 
Supernatant 
+ Blue Sepharose 
DEAE-cellulose 
QAE-Sephadex 
Sephadex G-150 
ADP-Sepharose 
268 49.2 13 186 9.21 5.34 (100) - 
95 26.9 2 556 0.105 256 19.4 48 
59 35.3 2 083 0.0279 1 265 15.8 237 
57 19.0 1 083 0.0104 1 827 8.2 342 
10.5 60.3 633 0.0056 10 768 4.8 2016 
280 56.5 15 820 7.21 7.84 (100) - 
50 270 13500 0.056 4 821 85 615 
50 197.6 9 880 0.017 11 624 62.5 1 483 
90 77.6 6 984 0.005 15 520 44 1 980 
18.7 360 6 732 0.020 18 000 42.5 2 297 
Units are lo-’ mol NADPH oxidized/mm at 37°C 
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Table 1 summarizes the results of a typical purifi- 
cation. Both purified enzymes migrated as single pro- 
tein bands on SDS and nondenaturing polyacrylamide 
gels. 
The molecular weights determined by SDS gel 
electrophoresis are, respectively, 50 000 for enzyme 
SSR 1 and 43 000 for enzyme SSR 2. The molecular 
weights of the native enzymes determined on poly- 
a&amide gels are, respectively, 54 000 and 45 000. 
The pH optima of enzyme SSR 1 are, respectively, 
5.5 for SSA reduction and 8.7 for GHB dehydrogena- 
tion (reverse reaction). For enzyme SSR 2, these 
values are, respectively, 5.0 and 8.1. The Km values 
determined under the above conditions are given in 
table 2. Table 3 shows the relative activities with 
various aldehyde substrates and table 4 compares the 
effect of various potential inhibitors on the two 
enzymes. 
Table 2 
Km values expressed in molarities 
SSA NADPH GHB NADP 
SSR 1 1.4 x lo+ 2.6 x 1O-6 1.5 x 1o-2 2.2 x 10-s 
SSR 2 2.8 x 10-s 2.4 x lO+ 1.2 x 1o-2 1.4 x 10-G 
Table 3 
Substrate specificities 
Substrate Relative activities 
SSR 2 SSR 1 
(Specific enzyme) (Non-specific enzyme) 
Succinic semialdehyde 100 46.5 
4Catboxy benzaldehyde nd 100 
2-Methyl succinic semialdehyde 76.5 85 
4-Nitrobenzaldehyde nd 62 
3-Pyridine carboxaldehyde nd 32 
Glyoxal nd 12.5 
D-Lactaldehyde nd 9.2 
3,4-Dihydroxyphenyl-acetaldehyde nd 8.9 
D-LGlyceraldehyde nd 3.4 
Iso-phthalaldehyde nd 3.1 
5-Hydroxyindolacetaldehyde nd nd 
Propionaldehyde nd nd 
Indolacetaldehyde nd nd 
3-Methoxy4-hydroxy-phenylglycolaldehyde nd nd 
Hydroxyphenylglycolaldehyde nd nd 
4-Anisaldehyde nd nd 
n-Valeraldehyde nd nd 
Phenyl-methyl-ketone nd nd 
Acetaldehyde nd nd 
Benzaldehyde nd nd 
4-Hydroxybenzaldehyde nd nd 
Glucose nd nd 
Lactose nd nd 
Arabinose nd nd 
Succinic semialdehyde/NADH 20 nd 
nd, not detected under our assay conditions 
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Comparative inhibition study 
I~ibito~ Percent ~hibition 
SSR 2 
Specific enzyme) 
SSR 1 
(Nonspecific enzyme) 
Barbiturates 
Barbital 0 
Pentobarbital 0 
Phenobarbital 0 
Amobarbital 0 
Miscellaneous 
4-Hydroxybenzaldehyde 55 
Oxalate 0 
Dipheny~yd~toinb 0 
~~orprorn~~e 29 
Pyrazol 0 
Diazepam 0 
4-Hydroxybutyrate 20 
ChloraI 0 
Valproate 10 
a Final cont. 10e3 M; b Final cont. 2 x 10T4 M 
80 
16 
72 
70 
68 
0 
63 
43 
0 
25 
21 
19 
96 
4. Discussion 
Enzyme SSR 1 exhibits a broad substrate specificity 
and is strongly ~bited by b~biturates and certain 
~ticon~s~t drugs. It is thus similar to many 
NADPHdependent aldehyde reductases (reviewed 
[ 131). However, enzyme SSR 2 shows a fairly high 
degree of specificity for SSA, and unlike the first 
enzyme, it is not appreciably inhibited by the various 
hypnotics/anticonvulsants tested, including valproate. 
This enzyme is thus similar to the SSA reductase 
isolated from human brain [S]. 
As valproate is an inhibitor of rat brain SSADH 
[14], its adm~istration might raise the endogenous 
level of SSA. If this is the case, it could explain the 
recent finding that adm~~tration of valproate to rats 
brings about some increase in cerebral GHB levels [ 151 
since we have shown that one of the enzymes capable 
of reducing SSA to GHB is not significantly inhibited 
by this drug. However, it is unlikely that GHB forma- 
tion contributes to the anticonvulsant effect of val- 
proate, since administration of this drug to rats has 
been shown to antagonise the epileptiform electro- 
corticogram patterns elicited by GHB administration 
Pa 
In view of the multiple effects of GHB on the cen- 
tral nervous ystem (reviewed 1171) the fmding of an 
enzyme in brain which is apparently specific for its 
biosynthesis of great interest. 
This work has been partially supported by a grant 
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